Researchers have created tiny metal-based particles that push cancer cells over the edge while leaving healthy cells mostly unharmed. The particles work by increasing internal stress in cancer cells ...

Singlera Genomics, a company focused on the development and application of novel DNA methylation technologies to genetic ...

A study by the Mildred Scheel Early Career Center group led by Dr. Mohamed Elgendy at the TUD Faculty of Medicine provides ...

BOLOGNA, Italy and HUNTINGDON VALLEY, Pa., Dec. 22, 2025 /PRNewswire/ -- Menarini Silicon Biosystems, a pioneer of cell-based liquid biopsy technology, ann ...

Marija Balic, MD, discusses how circulating tumor DNA assays for molecular residual disease detection have evolved in recent ...

Menarini Silicon Biosystems, a pioneer of cell-based liquid biopsy technology, announced today the publication in Clinical Cancer Research[1] of the CTC biomarker analysis from the PACE trial, a ...

Findings from a study on the utility of ultrasensitive circulating tumor DNA (ctDNA) as a predictive biomarker for patients ...

This year, there was a surge of new lung cancer treatments, more options for patients with earlier-stage disease, and growing ...

Natera, Inc. , a global leader in cell-free DNA and precision medicine, today announced the publication of findings from the randomized, phase III CALGB (Alliance)/SWOG 80702 study in JAMA Oncology.

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of findings from the randomized, phase III CALGB (Alliance)/SWOG 80702 study in ...

The 2025 San Antonio Breast Cancer Symposium brought plenty of data and bold new ideas to the thousands of clinicians, ...

Singlera Genomics, a company focused on the application of novel DNA methylation technologies to genetic diagnosis, with ...